Allergy Shots Can End Your Allergies. Here's the 3-to-5-Year Money and Logistics Map

Most allergy care manages symptoms forever; immunotherapy retrains the immune system and, for most who complete it, durably ends or dramatically reduces the disease. The catch is structural: it's a 3-to-5-year logistics-and-copays project, and the corpus's chronic-condition threads are full of treatments abandoned mid-course for exactly the frictions nobody priced upfront. Here's the whole map: what's covered, what the real costs are, and the tablet-versus-drops distinction that separates covered medicine from cash-pay marketing.

Testing first: covered, with one caveat

Skin-prick and blood (specific IgE) testing are covered by most plans and Medicare when a physician orders them as medically necessary for diagnosis and treatment planning, under normal specialist-visit cost sharing and network rules. The caveat: direct-to-consumer "food sensitivity" IgG panels are a different product with no diagnostic validity for allergy, not covered, and not a substitute; if symptoms are real, the allergist's workup is the covered and useful route.

Allergy shots: the covered workhorse, priced honestly

• Coverage: subcutaneous immunotherapy is standard covered medical care under commercial plans and Medicare Part B, billed as the serum (extract preparation) plus injection-administration visits.
• The schedule that sets the price: build-up means injections weekly or twice-weekly for roughly 6 to 12 months, then maintenance monthly for a total of 3 to 5 years. Multiply your plan's per-visit cost by ~40 first-year visits before starting: a $30 copay plan spends $1,200+ in year one, a plan that bills injection visits cheaply (many process shot-only visits at low or no copay) spends far less. Ask the exact question at billing: "how do injection-only visits process on my plan?"
• [Deductible-phase math](/blog/deductible-copay-coinsurance-out-of-pocket-max-explained) applies: starting build-up in a met-deductible autumn beats a fresh-deductible January on HDHPs.
• The 30-minute observation wait after each shot is a safety rule, and a real scheduling constraint: clinics with early/late shot hours exist and are worth choosing for adherence.
• Kids are strong candidates (immunotherapy can alter the allergic march), and school-hour logistics plus FMLA-intermittent time for parents are the real-world supports.

Under the tongue: the FDA line that decides coverage

1. FDA-approved sublingual tablets (grass, ragweed, dust mite, and peanut oral immunotherapy as its own category) are covered as pharmacy benefits on most formularies, with the usual tier and prior-auth machinery. First dose in-office, then home dosing: dramatically fewer visits, allergen-specific (they treat one thing). If your plan tiers them expensively, the pay-less playbook for prescriptions applies.
2. Compounded sublingual drops (custom multi-allergen mixes) are not FDA-approved, and insurance therefore almost never covers them: the subscription clinics advertising convenience are cash-pay businesses ($1,000 to $2,000+ a year), which is a legitimate consumer choice only when presented as one. HSA/FSA funds generally apply; "we'll give you a superbill" rarely converts to reimbursement for an off-label compounded product.
3. The decision logic: single dominant allergen with an approved tablet → tablets compete well; multiple allergens (the common case) → shots remain the covered, evidence-dense route; needle-phobia and distance from clinics → where the drops conversation honestly lives, with its price named.

Protecting the multi-year investment

Immunotherapy abandoned early buys little, so the adherence engineering is clinical: choose the clinic partly on shot-hour convenience, stack the vials before insurance changes (a plan switch mid-course means re-verifying serum and visit coverage; ask at open enrollment), keep the visit log since serum lots and reactions matter across years, and if you move, extracts can transfer to a new allergist with your records (the records playbook covers it). Year 3 to 5 completion is where the lasting-tolerance evidence lives; plan for the whole arc on day one.